• Contact
  • EPAD Academy
Top Bar Menu
TwitterFacebookYouTube
Search...
EPADEPAD
EPAD
European Prevention of Alzheimer's Dementia Consortium
  • Home
  • About
    • Welcome to EPAD
    • Project Objectives
    • Project Structure
    • EPAD Partners
    • Coordination & Management
    • EPAD Q&A
  • Our research
    • Participation in EPAD
      • Participation in EPAD Cohort
      • EPAD Study Visits
      • Trial Locations
      • Participation FAQs
    • The Participant’s Experience
      • The Research Participant Panel
      • EPAD Stories
    • The EPAD platform
      • The EPAD Platform
      • EPAD Benefits
      • Clinical Candidate Selection
      • EPAD FAQs
      • Research Resources
  • Open Access Data
    • Overview
    • Access
    • Data
    • MRI Images
  • Sample Access
  • News & Publications
    • Latest News
    • Newsletters
    • Publications
    • Videos
Menu back  

COVID-19 Update and online resources

2020-04-29News

The worldwide COVID-19 pandemic has inevitably impacted EPAD and its consortium members. The EPAD project management team is monitoring the situation closely. Most EPAD research and clinical trial activities had to stop as of early March as progressively universities across Europe closed, and the clinical sites were either closed or saw site staff redeployed to help fight this pandemic.

COVID-19: Sharing experiences and advices from EPAD member José Luis Molinuevo

“All participants from our observational studies, like EPAD, AMYPAD, ALFA+ study, etc., and trials, PENSA, AB1601, are not allowed, by law, to come in, hence from a safety perspective we are on good grounds. We are aware of the impact on our studies, so we are working hard adapting them with the necessary protocol amendments to ensure their viability and validity after the crisis. Our IT teams are working on existing data to clean it and make it accessible to our research team, who is focusing on analysis and writing results from their homes”, says Dr José Luis Molinuevo, scientific director of the Alzheimer’s Prevention Program at BBRC.

Moreover, Molinuevo has been part of a correspondence letter in The Lancet, together with Alzheimer’s Disease International (ADI) and experts in the field of dementia. They suggested several measures for people living with dementia, as they are particularly vulnerable to the COVID-19 pandemic. You can read the correspondence here.

He has also published, together with ADI, a position paper on COVID-19 and dementia, with the aim to help families consider key issues when planning care for their loved ones with dementia during this pandemic. You can read the paper here.

How COVID-19 has affected the dementia research at the Center of Dementia Prevention in Edinburgh?

“When COVID-19 arrived in the UK, and with an impending lockdown looming, our sponsor office announced the suspension of all study activity. This means all of our ongoing studies with face-to-face visits have been temporarily halted and we have transitioned the team to work from home. However, the Centre for Dementia Prevention team at the University of Edinburgh always rise to a challenge and although we are missing our participant visits, we’ve been able to creatively continue our work from our home offices. Before lockdown we were looking forward to launching a study looking at public opinions on data sharing in health care research. Initially this was planned as a face to face series of workshops, but we have redesigned the programme to run online. We also have lots of exciting data to look at and ask important research questions of- even though we cannot complete face to face visits with our participants, their data is still contributing hugely to dementia research during this time. We’ve also been able to spend some time on some fun communications projects during this time- we had some micromodules included in the Edinburgh International Science Festival and are working on a website relaunch as a portal to communicate our research work to the public. We are really looking forward to being back in the office soon, but COVID19 won’t stop our efforts to understand more about how we can prevent dementia”, shared Sarah Gregory (EPAD Study Coordinator), Clare Dolan (Research Assistant) and Hannah Pullen (Assistant Psychologist).

Mercè Boada, Principal Investigator of the EPAD project at Fundació ACE (Barcelona), shares her experiences of COVID-19 lockdown

At Fundació ACE, they are using telemedicine to perform follow-up on the patients and research participants. Supported by their younger family members, the patients are able to use the telemedicine services to attend consultations and obtain information about their care. The team of social workers provides emotional support and helps people complete the paperwork required to obtain support from the local authorities. The team is also experiencing ethical challenges related to the continuation of the clinical trials, which have been suspended. This was a very difficult decision to make, but they had to consider that the participant population is vulnerable and at high risk of COVID-19 morbidity and mortality. So far, they have suspended their activities and have established the logistics for new possible scenarios in the short and long term. You can find more information here.

Alzheimer Europe has launched a website section with key resources and rung the alarm about discriminatory practices in intensive care settings during the COVID-19 pandemic

In order to support people with dementia, carers, care professionals and national Alzheimer’s associations during the ongoing COVID-19 situation, our partner Alzheimer Europe has put together a range of valuable online resources with helpful information, tips and guidelines. Ten categories have been published including 1) information for people with dementia; 2) advice for caregivers and family members; 3) information for minority ethnic groups; 4) COVID-19 and intellectual disabilities, 5) Mental health resources; 6) COVID-19 in numbers: epidemiology; 7) Global resources; 8) EU resources; 9) National country resources and 10) General, scientific and ethical resources. These can be found here.

During these challenging times, there are a number of accurate and up-to-date information on the coronavirus outbreak and the long list of resources that have been gathered shows the invaluable work provided by national Alzheimer’s associations, pharmaceutical companies and government agencies during the COVID-19 pandemic.

In addition, Alzheimer Europe has rung the alarm about discriminatory practices in intensive care settings during the COVID-19 pandemic. The full position of Alzheimer Europe is online here. On 14 April 2020, the Alzheimer Europe Board adopted recommendations for Alzheimer associations, health and social care professionals on how to promote the wellbeing of people with dementia and carers during the COVID-19 pandemic. For the development of its recommendations, the Alzheimer Europe Board built on in-depth discussions with its member organisations and ministry officials from the European Governmental Expert Group on Dementia who shared some of the innovative ways in which associations and governments continue to provide support to people with dementia. The full recommendations adopted by the Alzheimer Europe Board are online here.

Jean Georges, Executive Director of Alzheimer Europe commented: “I am in awe at how quickly Alzheimer associations and health and social care professionals have responded to the COVID-19 challenge and continue to provide essential information, support and care to people with dementia and their carers. They deserve the full support of national governments and I hope our recommendations provide some guidance on how to promote the wellbeing of people with dementia and carers in these difficult times.”

Some additional useful resources:

  • Up-to-date advice on COVID-19 from the WHO
  • The coronavirus response by the European Commission
  • What is the industry in Europe doing to help in the fight against the coronavirus?
  • ADI offers advice and support during COVID-19
  • Tips for dementia caregivers
Share this post
FacebookTwitterLinkedInGoogle+
Related posts
Analysis of multiple steroids in saliva in the EPAD study
2023-03-02
Hormone Replacement Therapy could ward off Alzheimer’s among at-risk women
2023-01-16
Associations between Mediterranean diet and cognition in the pan-European EPAD LCS
2022-12-09
Bruno Steinkraus
Interview with Dr. Bruno Steinkraus, Chief Scientific Officer at Hummingbird Diagnostics GmbH
2022-11-25
New paper defining and discussing the substantial assets of the EPAD project is out!
2022-11-23
New paper using the EPAD data for an analysis of sleep quality and efficiency
2022-11-03
Latest News
  • Analysis of multiple steroids in saliva in the EPAD study
    2023-03-02
  • Hormone Replacement Therapy could ward off Alzheimer’s among at-risk women
    2023-01-16
  • Associations between Mediterranean diet and cognition in the pan-European EPAD LCS
    2022-12-09
  • Bruno Steinkraus
    Interview with Dr. Bruno Steinkraus, Chief Scientific Officer at Hummingbird Diagnostics GmbH
    2022-11-25
  • New paper defining and discussing the substantial assets of the EPAD project is out!
    2022-11-23
View the EPAD Brochure
thumbnail of EPAD brochure
Speak to the EPAD team
thumbnail of speech bubbles
Twitter
Twitter
EPAD
EPAD
@IMI_EPAD

📢@imi_epnd has launched its Cohort Catalogue, a central, open & accessible repository for researchers to discover studies & search metadata. Currently 67 research cohorts from 17 countries across Europe including @IMI_EPAD-VUmc participants ⬇️ eurekalert.org/news-releases/… twitter.com/imi_epnd/statu…

reply retweet favorite
9:56 am · 2023-03-14
Twitter
EPAD
EPAD
@IMI_EPAD

NEW paper published in @MetabolitesMDPI using LC-MS/MS method to determine salivary steroids using @IMI_EPAD samples. Congratulations @GregorySarah @zinghomer @guider50 @scottgdenham👏 @EdMassSpecCore @IMI2_NEURONET @IHIEurope #mdpimetabolites mdpi.com/2133518

reply retweet favorite
12:55 pm · 2023-03-02
Twitter
EPAD
EPAD
@IMI_EPAD

"There is a growing consensus that individual research results that are potentially relevant should be reported to research participants” & “Our work was positively received by the EPAD partners, and formed the basis for the set-up & the conduct of the study,” said Eline Bunnik

reply retweet favorite
10:32 am · 2023-01-31
Twitter
EPAD
EPAD
@IMI_EPAD

Have a look on the @IHIEurope newsletter including a spotlight on IMI results from projects on diabetes @HypoResolve and #Alzheimer’s disease @IMI_EPAD @IMI_AMYPAD ⬇️ Read it: bit.ly/3jeaxdM twitter.com/IHIEurope/stat…

reply retweet favorite
10:30 am · 2023-01-31
Twitter
EPAD
EPAD
@IMI_EPAD

17 centres have contributed to the @IMI_AMYPAD Prognostic Study across 11 Parent Cohorts including @IMI_EPAD. Have a look on the latest AMYPAD paper published in @FrontNeurol ⬇️ twitter.com/IMI_AMYPAD/sta…

reply retweet favorite
8:19 am · 2023-01-30
Workstream Progress
Workstream 120%
Workstream 232%
Workstream 310%
Workstream 446%
Contact us

Submitclear

Recent Posts
  • Analysis of multiple steroids in saliva in the EPAD study
  • Hormone Replacement Therapy could ward off Alzheimer’s among at-risk women
  • Associations between Mediterranean diet and cognition in the pan-European EPAD LCS
  • Interview with Dr. Bruno Steinkraus, Chief Scientific Officer at Hummingbird Diagnostics GmbH
  • New paper defining and discussing the substantial assets of the EPAD project is out!
Recent Comments
  • The EPAD genomic data is now available on the Alzheimer’s Disease Workbench on The EPAD genomic data is now available on the Alzheimer’s Disease Workbench
  • ADDI celebrates one year of achievements – Neuronet on ADDI celebrates one year of achievements
  • EPAD dataset is now available on the Alzheimer’s Disease Workbench on The final EPAD dataset is now available on the Alzheimer’s Disease Workbench
  • The final EPAD dataset is now available to the entire research community on The final EPAD dataset is now available to the entire research community
  • The ERC has awarded an ERC grant to identify age-related human blood factors as a therapeutic target for Alzheimer’s disease – Neuronet on New ERC starting grant to identify age-related human blood factors as a therapeutic target for Alzheimer’s disease
Archives
  • March 2023
  • January 2023
  • December 2022
  • November 2022
  • October 2022
  • September 2022
  • August 2022
  • July 2022
  • June 2022
  • May 2022
  • April 2022
  • March 2022
  • January 2022
  • November 2021
  • October 2021
  • September 2021
  • August 2021
  • July 2021
  • June 2021
  • May 2021
  • April 2021
  • March 2021
  • February 2021
  • November 2020
  • October 2020
  • September 2020
  • July 2020
  • June 2020
  • April 2020
  • March 2020
  • February 2020
  • January 2020
  • December 2019
  • November 2019
  • October 2019
  • September 2019
  • August 2019
  • July 2019
  • June 2019
  • May 2019
  • April 2019
  • March 2019
  • February 2019
  • January 2019
  • December 2018
  • November 2018
  • October 2018
  • September 2018
  • August 2018
  • July 2018
  • June 2018
  • May 2018
  • April 2018
  • March 2018
  • February 2018
  • January 2018
  • December 2017
  • November 2017
  • October 2017
  • September 2017
  • July 2017
  • June 2017
  • May 2017
  • April 2017
  • March 2017
  • February 2017
  • January 2017
  • December 2016
  • November 2016
  • October 2016
  • September 2016
  • August 2016
  • July 2016
  • June 2016
  • May 2016
  • April 2016
  • March 2016
  • February 2016
  • January 2016
  • December 2015
  • November 2015
  • October 2015
  • September 2015
  • August 2015
  • June 2015
  • May 2015
  • April 2015
Categories
  • EPAD Academy
  • News
Meta
  • Log in
  • Entries feed
  • Comments feed
  • WordPress.org
Copyright © 2015-2021 EPAD | Created by CMAST and Aridhia
  • Acronyms
  • Legal Notice
  • Privacy Policy
Bottom Menu

efpia-logo EU imi logo

This work has received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking EPAD grant agreement nº 115736

This website uses cookies to improve your experience. Accept Read More
Privacy & Cookies Policy

Privacy Overview

This website uses cookies to improve your experience while you navigate through the website. Out of these, the cookies that are categorized as necessary are stored on your browser as they are essential for the working of basic functionalities of the website. We also use third-party cookies that help us analyze and understand how you use this website. These cookies will be stored in your browser only with your consent. You also have the option to opt-out of these cookies. But opting out of some of these cookies may affect your browsing experience.
Necessary
Always Enabled
Necessary cookies are absolutely essential for the website to function properly. This category only includes cookies that ensures basic functionalities and security features of the website. These cookies do not store any personal information.
Non-necessary
Any cookies that may not be particularly necessary for the website to function and is used specifically to collect user personal data via analytics, ads, other embedded contents are termed as non-necessary cookies. It is mandatory to procure user consent prior to running these cookies on your website.
SAVE & ACCEPT